Sana Biotechnology Financial Ratios
NASDAQ: SANAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.790.00 (0.00%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Sana Biotechnology ratio analysis
Return on equity reached -151.8%, meaning Sana Biotechnology generated -1.52 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Sana Biotechnology financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / book | 6.60 | 1.58 | 2.76 | 1.49 | 3.54 | — | — |
| Return on equity (ROE) | -151.8% | -106.5% | -98.5% | -54.0% | -48.9% | — | — |
| Return on assets (ROA) | -58.6% | -53.2% | -50.1% | -32.8% | -31.5% | -39.1% | — |
| Current ratio | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | — |